BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Agenus Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Agenus Inc.'s drugs run\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05608044-2380@assetmemo.bio
DTSTAMP:20261121T005735Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Balstilimab: Phase 2 readout est. (NCT05608044)
DESCRIPTION:Balstilimab\, phase 2\, Colorectal Cancer.\nStudy: A Study of B
 otensilimab and Balstilimab for the Treatment of Colorectal Cancer\nEstima
 ted primary completion: September 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/balstilimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05608044
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
